Referred to the House Committee on Energy and Commerce.
The bill amends the Federal Food, Drug, and Cosmetic Act to expand and modernize the accredited third‑party auditor program.
It broadens the definition of eligible entities (foreign and domestic), clarifies "regulatory audits," removes some limits on how third‑party certifications may be used for imports and VQIP participation, requires the Secretary to set up accreditation body recognition within two years, and adds certification status to facility inspection information.
Focused regulatory modernization with modest fiscal impact improves prospects, but potential consumer-safety scrutiny and Senate process uncertainty reduce odds.
Relative to its intended legislative type, this bill clearly effects substantive policy change by amending the Federal Food, Drug, and Cosmetic Act to broaden third‑party certification and audit uses and by inserting related conforming edits. It integrates well with the existing statutory framework and assigns implementation to the Secretary, including a 2‑year deadline for recognition processes. However, it provides limited procedural detail, no fiscal or resourcing provisions, and minimal new accountability or anti‑abuse safeguards.
Progressives emphasize privatization risks and need for public safeguards
Progressives emphasize privatization risks and need for public safeguards
Likely skeptical.
Supports improved food safety but worried this shifts oversight to private auditors and could weaken FDA enforcement.
Would seek stronger public safeguards and transparency.
Pragmatic conditional support.
Views third‑party accreditation as useful to extend capacity if accompanied by clear FDA oversight, performance metrics, and safeguards against uneven auditing quality.
Generally favorable.
Sees expansion of accredited third‑party audits as efficient, pro‑trade, and lowering regulatory friction while maintaining a federal backstop.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Focused regulatory modernization with modest fiscal impact improves prospects, but potential consumer-safety scrutiny and Senate process uncertainty reduce odds.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize privatization risks and need for public safeguards
Focused regulatory modernization with modest fiscal impact improves prospects, but potential consumer-safety scrutiny and Senate process un…
Relative to its intended legislative type, this bill clearly effects substantive policy change by amending the Federal Food, Drug, and Cosmetic Act to broaden third‑party certification and audit uses and by inserting re…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.